Lantheus Holdings to Present at Upcoming Investor Conferences

November 1, 2018 at 4:05 PM EDT

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Nov. 1, 2018-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced that Company management will participate in analyst-led fireside chat discussions at the following investor conferences:

  • Credit Suisse Securities Healthcare Conference
    Tuesday, November 13, 2018 at 4:35 p.m. MT
    Robert J. Marshall Jr., Chief Financial Officer and Treasurer
    Location: Scottsdale, AZ
  • Jefferies London Healthcare Conference
    Wednesday, November 14, 2018 at 9:20 a.m. GMT
    Mary Anne Heino, President and Chief Executive Officer
    Location: London, UK

To access a live webcast of the presentation, please visit the Investors section of the company’s website at www.lantheus.com. A replay of the webcast will be available on the Company’s website for 30 days following the live presentation.

About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.
Lantheus Holdings, Inc. is the parent company of LMI, a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, including the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. The Company is headquartered in North Billerica, Massachusetts with offices in Puerto Rico and Canada. For more information, visit www.lantheus.com.

Source: Lantheus Holdings, Inc.

Lantheus Holdings, Inc.
Meara Murphy, 978-671-8508
Director, Investor Relations & Corporate Communications